Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
This article was originally published in PharmAsia News
Executive Summary
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical